Here is our regular summary of content of relevance to neurology from the July 2025 issue of the European Medicines Agency’s (EMA) newsletter.
Key EMA News Updates:
EMA Management Board: highlights of June 2025 meeting: During its June 2025 session, the EMA Management Board welcomed the African Medicines Agency Governing Board as an observer, strengthening international regulatory collaboration. The Board also adopted the 2024 annual activity report of the Executive Director and appointed Aimad Torqui of the Netherlands as its new vice-chair.
Click here for more details: EMA Management Board: highlights of June 2025 meeting | European Medicines Agency (EMA)
EMA begins review of sodium oxybate for alcohol dependence: The review will assess its effectiveness in treating alcohol withdrawal and maintaining abstinence, while also evaluating measures to reduce abuse risk.
Click here for more details: EMA starts review of sodium oxybate in alcohol dependence | European Medicines Agency (EMA)
New EMA webpage on paediatric cancer medicines: a new page outlines how the EMA supports the development of cancer treatments for children, with details on clinical trial initiatives and global collaboration.
Click here for more details: Developing cancer medicines for children | European Medicines Agency (EMA)
EMA web accessibility statement: the EMA is committed to making its website accessible for all users, including those with cognitive or physical disabilities, and welcomes feedback to improve accessibility.
Click here for more details: Accessibility | European Medicines Agency (EMA)
